Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 8;10(9):1527.
doi: 10.3390/children10091527.

Similarities and Differences between Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease Shock Syndrome

Jin Lee  1   2 , Beom Joon Kim  1   3 , Kyoung-Soon Cho  1   4 , Jung Woo Rhim  1   5 , Soo-Young Lee  1   4   6 , Dae Chul Jeong  1   6   7
Affiliations

Similarities and Differences between Multisystem Inflammatory Syndrome in Children (MIS-C) and Kawasaki Disease Shock Syndrome

Jin Lee et al. Children (Basel). .

Abstract

This study aimed to investigate the characteristics of COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease shock syndrome (KDSS) and to compare the similarities and differences between the two diseases. The incidence of KDSS and MIS-C was also estimated. Medical records of patients diagnosed with MIS-C or KDSS at four hospitals from January 2013 to December 2022 were retrospectively reviewed. Thirty-one patients were enrolled in the study in either an MIS-C group (n = 22) or a KDSS group (n = 9). The incidence of KDSS in KD was 0.8% (9/1095) and the incidence of MIS-C versus KD was 10.2% (22/216). Compared with the MIS-C group, the KDSS group had longer hospital stays and more severe systemic inflammation (e.g., anemia, elevated C-reactive protein, hypoalbuminemia, and pyuria) and organ dysfunction (e.g., number of involved organs, shock, vasoactive infusion, and intensive care unit admission). All patients in the MIS-C group, but none in the KDSS group, including two patients during the COVID-19 pandemic, had laboratory evidence of SARS-CoV-2 infection. MIS-C and KDSS shared demographic, clinical, and laboratory characteristics; organ dysfunction; treatment; and outcomes. Overall severity was more severe in patients with KDSS than in those with MIS-C. The most important difference between MIS-C and KDSS was whether SARS-CoV-2 was identified as an infectious trigger.

Keywords: Kawasaki disease; Kawasaki disease shock syndrome; multisystem inflammatory syndrome in children.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The annual (first- and second-half) incidences of KDSS and MIS-C compared with KD. A total of 9 patients with KDSS were hospitalized during the 10-year study period (i.e., pre-COVID-19 pandemic + COVID-19 pandemic) and 22 patients with MIS-C were hospitalized during the COVID-19 pandemic. Dividing by the number of patients with KD, the incidence of KDSS was 0.8% (9/1095) and the incidence of MIS-C was 10.2% (22/216). COVID-19, coronavirus disease 2019; KDSS, Kawasaki disease shock syndrome; MIS-C, multisystem inflammatory syndrome in children; KD, Kawasaki disease.
Figure 2
Figure 2
Relationships between KD, KDSS, and MIS-C. (A) KD is characterized by KD-like features and systemic inflammation. Infectious triggers are expected to play an important role in the pathogenesis of KD. (B) KDSS is diagnosed when shock presenting as organ dysfunction is observed in patients with KD-like features and systemic inflammation. (C) MIS-C is diagnosed when SARS-CoV-2 is identified in patients with KD-like features, systemic inflammation, and organ dysfunction such as shock. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; KD, Kawasaki disease; KDSS, Kawasaki disease shock syndrome; MIS-C, multisystem inflammatory syndrome in children.
See this image and copyright information in PMC

References

    1. Dufort E.M., Koumans E.H., Chow E.J., Rosenthal E.M., Muse A., Rowlands J., Barranco M.A., Maxted A.M., Rosenberg E.S., Easton D., et al. Multisystem inflammatory syndrome in children in New York state. N. Engl. J. Med. 2020;383:347–358. doi: 10.1056/NEJMoa2021756. - DOI - PMC - PubMed
    1. Schlapbach L.J., Andre M.C., Grazioli S., Schöbi N., Ritz N., Aebi C., Agyeman P., Albisetti M., Bailey D.G.N., Berger C., et al. Best Practice Recommendations for the diagnosis and management of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS; multisystem inflammatory syndrome in children, MIS-C) in Switzerland. Front. Pediatr. 2021;9:667507. doi: 10.3389/fped.2021.667507. - DOI - PMC - PubMed
    1. Verdoni L., Mazza A., Gervasoni A., Martelli L., Ruggeri M., Ciuffreda M., Bonanomi E., D’Antiga L. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 Epidemic: An observational cohort study. Lancet. 2020;395:1771–1778. doi: 10.1016/S0140-6736(20)31103-X. - DOI - PMC - PubMed
    1. Zhang Q.Y., Xu B.W., Du J.B. Similarities and differences between multiple inflammatory syndrome in children associated with COVID-19 and Kawasaki disease: Clinical presentations, diagnosis, and treatment. World J. Pediatr. 2021;17:335–340. doi: 10.1007/s12519-021-00435-y. - DOI - PMC - PubMed
    1. Riphagen S., Gomez X., Gonzalez-Martinez C., Wilkinson N., Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395:1607–1608. doi: 10.1016/S0140-6736(20)31094-1. - DOI - PMC - PubMed